On January 2, 2019 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) reported that it will present at the 37th Annual J.P. Morgan Healthcare Conference at 4:00 PM PT (7:00 PM ET) on Tuesday, January 8, 2018. Live audio of the presentation can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com (Press release, Pacira Pharmaceuticals, JAN 2, 2019, View Source;p=irol-newsArticle&ID=2381850 [SID1234532345]). A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2018 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported that John A. Orwin, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 1:30 p.m. Pacific Standard Time in San Francisco, CA (Press release, Atreca, JAN 2, 2019, View Source [SID1234532367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2019 Alexion Pharmaceuticals (Nasdaq: ALXN) reported that management will present at the (Press release, Alexion, JAN 2, 2019, View Source [SID1234532437])9 at 7:30 a.m., PT (Press release, Alexion, JAN 2, 2019, View Source [SID1234532437]). A breakout question and answer session will immediately follow the formal presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Audio webcasts of the presentation and breakout question and answer session will be available live. You can access the webcasts at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

On January 2, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 7:30 a.m. PT at the Westin St. Francis in San Francisco (Press release, Karyopharm, JAN 2, 2019, View Source [SID1234532330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On January 2, 2019 Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference (Press release, Moderna Therapeutics, JAN 2, 2019, View Source [SID1234532368]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bancel’s presentation will take place on Tuesday, January 8, 2019 at 10:30 a.m. PT in the Colonial Room at The Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session can be accessed on the investors section of Moderna’s website at investors.modernatx.com. A replay of the webcast also will be archived on Moderna’s website for up to 30 days following the presentation.